FDA Cites Amgen for Misleading Vectibix Cancer Drug Video
Cancer patients should verify drug risks and usage criteria with their doctors.
Updated on Oct. 27, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies provide accurate safety information in their drug advertisements?
On August 12, 2026, the FDA issued a warning letter to Amgen, citing a misleading promotional video for the cancer drug Vectibix. The video failed to include essential information about serious safety risks and specific tumor testing requirements for patients.
Why it matters
The FDA warning highlights the importance of full disclosure regarding drug risks and usage limitations to ensure patient safety. Omissions in promotional materials can leave patients unaware of significant medical realities, such as the need for specific genetic testing before treatment.
The FDA identified that an Amgen promotional video for Vectibix omitted critical warnings and patient usage limits. The agency is currently investigating how the company will provide corrective communications to address these regulatory violations.
The players
Amgen
A global biotechnology company that develops and manufactures targeted therapies for cancer and other serious illnesses.
Food and Drug Administration
The federal agency responsible for protecting public health by regulating the safety and marketing of prescription drugs.
The details
Vectibix is a monoclonal antibody used in cancer treatment that requires specific tumor testing to determine if a patient is an appropriate candidate. The drug carries a boxed warning for severe skin reactions and potential risks including fatal infusion reactions, kidney failure, and lung disease. Promotional materials are required to provide a balanced presentation of these risks alongside benefits, which the FDA determined the video failed to do.
Timeline
August 12, 2026: The FDA issued a warning letter to Amgen regarding Vectibix.
October 27, 2026: The FDA warning letter was made public.
15 working days after notice: The deadline for Amgen to submit a written response to the FDA.
Health Landscape
This enforcement action sits within the long-standing regulatory framework that mandates pharmaceutical companies provide fair balance in drug promotion. It reinforces existing standards that prevent companies from emphasizing clinical benefits while obscuring severe risks or usage criteria.
If you or a loved one are prescribed Vectibix, it is important to discuss the specific tumor testing requirements and known risks with your oncologist. Ensure you understand all contraindications before starting treatment and consult your doctor about any concerns regarding your care plan.
The takeaway
When discussing any new oncology treatment, ask your physician about the specific genetic or tumor markers required to determine if the drug is appropriate for your situation. Always review the official prescribing information or medication guide rather than relying solely on promotional videos or marketing materials.
Further reading
For more information on the regulations governing cancer drug safety and information, visit our Cancer page.
Source note: This article includes information reported by WTAQ News Talk | 97.5 FM · 1360 AM | Green Bay, WI.
Live Poll
Do you trust that pharmaceutical companies provide accurate safety information in their drug advertisements?
